AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
Here's Why You Should Retain ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies. However, limited commercial expertise is a woe.
Cardinal Health (CAH) to Extend Warehouse Footing With New Center
by Zacks Equity Research
Cardinal Health's (CAH) new distribution center to support the company's at-Home Solutions business.
BD's (BDX) Latest Product to Transform Research Outcome
by Zacks Equity Research
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.
If You Invested $1000 in AMN Healthcare Services 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Surging Earnings Estimates Signal Upside for AMN Healthcare (AMN) Stock
by Zacks Equity Research
AMN Healthcare (AMN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program
by Zacks Equity Research
LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.
Cooper Companies (COO) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal second-quarter earnings reflect solid segmental performance.
Phibro (PAHC) Business Hurt by Macro Issues, FX Fluctuations
by Zacks Equity Research
The increase in raw material costs and freight costs continues to pose challenges for Phibro (PAHC).
Accuray's (ARAY) New Tie-Up to Augment Treatment Planning
by Zacks Equity Research
Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.
Leverage Relative Price Strength With These 5 Top Stocks
by Nilanjan Choudhury
Kronos Worldwide (KRO), Ulta Beauty (ULTA), AMN Healthcare Services (AMN), Marathon Petroleum (MPC) and Sanderson Farms (SAFM) are five stocks with explosive relative price strength.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.
Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both of its segments.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
DexCom (DXCM) to Boost Diabetes Management With New Coverage
by Zacks Equity Research
DexCom's (DXCM) G6 CGM System gets public coverage through Prince Edward Island's Diabetes Glucose Sensor Program, which can aid in effective diabetes management.
Abbott (ABT) Receives FDA Nod for FreeStyle Libre 3 System
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 system offers greater accuracy and easier application compared with other CGMs.
Here's Why Investors Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Here's Why Investors Should Retain Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.
Stryker's (SYK) Q Guidance System Receives FDA Approval
by Zacks Equity Research
Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during image-guided surgery following the receipt of the FDA approval.
Thermo Fisher (TMO) North America Sales Grow, Margin Woe Stays
by Zacks Equity Research
Thermo Fisher (TMO) witnesses core business strength across segments, end markets, and geographies.
Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Factors that Make UnitedHealth Group (UNH) an Attractive Bet Now
by Zacks Equity Research
UnitedHealth Group (UNH) continues to benefit from sustained top-line growth, a growing membership, and a strong cash position.
Here's Why Investors Should Retain Illumina (ILMN) Stock Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.
Wall Street Analysts See a 44% Upside in AMN Healthcare (AMN): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 43.7% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.